Sagimet Biosciences Inc (SGMT)
NASDAQHealth CareBiotechnologySnapshot 2026-10-30
$9.92-4.89%
Close 2026-10-30 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-30
Research Workspace
Put SGMT beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisThis stock is volatile — it swings about 2% on a typical day and fell roughly 48% in its worst 12-month stretch.
View RiskDenifanstat’s acne program needs Phase 3 progress to support SGMT’s growth case. Recent financial performance is weak, and the company was unprofitable over the past year. The latest Q2 FY2026 GAAP loss beat consensus, with a 7.1% surprise. A clean valuation multiple is unavailable, so the requested multiple comparison cannot be established. The price is roughly in line with the growth we forecast. A next-quarter miss probability of 38% and conflicting trial signals mark specific risks. Peer multiples imply a price about 53% above where it trades. Our read remains intact; this read is provisional.
Trailing returns as of 2026-10-30. SGMT is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 12 analysts currently covering SGMT (as of Oct 2026).
Based on 4 Wall Street analysts offering 12-month price targets for SGMT in the last 4 months.
Continue this research
Compare SGMT with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| SGMT Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put SGMT next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Initiate Phase 3 trial for denifanstat in moderate to severe acne
Price target increase supports Phase 3 trial for acne drug.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $9.92
The last 12 months of price, then the range of analyst 12-month targets from today’s $9.92.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Threatens: Initiate Phase 3 trial for denifanstat in moderate to severe acne
Stock price target cut indicates concerns over trial data.
Advances: Initiate Phase 3 trial for denifanstat in moderate to severe acne
Upgrade indicates confidence in acne drug potential.
Advances: Initiate Phase 3 trial for denifanstat in moderate to severe acne
Positive data supports Phase 3 trial initiation for denifanstat.
Advances: Initiate Phase 3 trial for denifanstat in moderate to severe acne
Analyst upgrade supports Phase 3 trial for acne drug.
Advances: Initiate Phase 3 trial for denifanstat in moderate to severe acne
FDA clearance is crucial for advancing Phase 3 trial.
Advances: Initiate Phase 3 trial for denifanstat
Supports the case for denifanstat's potential.